Ocular Therapeutix (OCUL) Misses Q2 EPS by 12c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BMY
5. BYD
6. SPOT
7. WCN
8. TSCO
9. BE
10. SPY

Go back to Ocular Therapeutix (OCUL) Misses Q2 EPS by 12c

Ocular Therapeutix™ Reports Second Quarter 2015 Financial Results

August 10, 2015 4:05 PM EDT

Clinical Programs Advance with Patient Enrollment Finalized in Three Clinical Trials: Phase 3 Allergic Conjunctivitis Trial, Phase 2b Glaucoma Trial and Phase 2 Inflammatory Dry Eye Trial

Follow-on Public Offering of 4 Million Shares Completed

Conference Call Today at 5:00 pm Eastern Time

BEDFORD, Mass.--(BUSINESS WIRE)-- Ocular Therapeutix, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced financial results for the second quarter ended June 30, 2015.

We continued... More